Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.
Ambagon Therapeutics, a US-based biotech developer using small molecules to unlock disordered protein targets, launched last week with $85m in series A funding to commercialise research conducted at University of California, San Francisco and Eindhoven University of Technology. The round’s backers included Merck and Co’s MRL Ventures Fund and fellow pharmaceutical firm AbbVie’s corporate VC…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
